{"id":"W2913874229","doi":"10.1200/jco.2019.37.4_suppl.481","title":"CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; Hôpital Charles-Le Moyne; University of Saskatchewan; Université de Montréal; Nova Scotia Cancer Centre; Hôpital du Sacré-Cœur de Montréal; University of Ottawa; McGill University; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; BC Cancer Agency; Moncton Hospital","funders":"","keywords":"Medicine; Tremelimumab; Irinotecan; Internal medicine; Hazard ratio; Refractory (planetary science); Durvalumab; Oxaliplatin; Oncology; Colorectal cancer; Gastroenterology; Clinical endpoint; Randomized controlled trial; Cancer; Confidence interval; Immunotherapy; Ipilimumab; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009851322,0.001511403,0.002510424,0.0003971801,0.0003555201,0.0009656165,0.0009524985,0.001246127,0.00654725],"category_scores_gemma":[0.001002578,0.0005089122,0.001067019,0.0004422733,0.0007235853,0.0006974509,0.0003069156,0.002707963,0.001331794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001373515,"about_ca_system_score_gemma":0.00156934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003151382,"about_ca_topic_score_gemma":0.009520673,"domain_scores_codex":[0.9996322,0.0001769528,0.00001313126,0.00006047114,0.00003081496,0.0000863741],"domain_scores_gemma":[0.9995215,0.00008304914,0.0001021088,0.00002620645,0.00002486022,0.0002421991],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9657305,0.005583412,0.0009220782,0.0007210892,0.0005535844,0.00007226381,0.00003744991,0.0005224136,0.003773018,0.0001713238,0.002778772,0.01913409],"study_design_scores_gemma":[0.947794,0.048035,0.00192769,0.00003121307,0.0003011045,0.00006676968,0.00001679713,0.0004332667,0.0002393302,0.00008469151,0.001057078,0.00001313301],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804709,0.005157345,0.000410416,0.001289387,0.0007553048,0.004168745,0.00228637,0.0001989916,0.005262614],"genre_scores_gemma":[0.9784207,0.002919469,0.00117296,0.00158184,0.0005393183,0.004017561,0.002870581,0.00004530104,0.008432268],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00654725,"threshold_uncertainty_score":0.02190268,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05959807721354623,"score_gpt":0.4340736936208993,"score_spread":0.3744756164073531,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}